Zydus receives final approval from USFDA for Loperamide Hydrochloride Capsules
Loperamide Hydrochloride Capsules USP, 2 mg had annual sales of US $34.7 million in the United States
Loperamide Hydrochloride Capsules USP, 2 mg had annual sales of US $34.7 million in the United States
Diclofenac epolamine topical system 1.3% offers patients a non-opioid topical treatment
Longer-term survival results underscoring role of KEYTRUDA (pembrolizumab) in multiple cancer types, including advanced nonsquamous non-small cell lung cancer (KEYNOTE-189)
The study demonstrated that patients who received NONS had significant reduction in viral load within 24 hours, which was sustained over seven days of treatment.
This is the 142nd ANDA (including 8 tentative approvals received) out of Eugia Pharma Specialty Group (EPSG) facilities, manufacturing both oral and sterile specialty products.
Transcatheter Mitral valve procedure allows intervention on patients who are unsuitable or high risk for open heart surgery
The proposed transaction involves the sale of the global biosimilars portfolio of Viatris to Biocon Biologics
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Motrin Oral Suspension, 100 mg/5 mL, of McNeil Consumer Healthcare (McNeil)
Pemetrexed for injection is indicated for the treatment of Antineoplastics (medications used to treat cancer)
Subscribe To Our Newsletter & Stay Updated